ERBB2 and breast carcinoma: Consistently, our data in the current study demonstrated that ganetespib significantly blocks oncogenic cellular processes, including cell proliferation, cell cycle progression, cell survival, and RTK signaling, and potentiates the anti-cancer effects of lapatinib in ErbB2+ BT474 and SKBR3 breast cancer cells.